{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T17:43:12Z","timestamp":1789753392693,"version":"4.0.1"},"reference-count":90,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T00:00:00Z","timestamp":1683072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Targeted therapy and immunotherapy have redefined cancer treatment. While they have enhanced tumor response and improved survival rates in many cancer types, toxicities continue to occur, and these often involve the oral cavity. Broadly reported as \u201cmucositis\u201d or \u201cstomatitis,\u201d oral toxicities induced by targeted therapies differ clinically and mechanistically from those associated with conventional chemotherapy. Manifesting primarily as mucosal lesions, salivary gland hypofunction, or orofacial neuropathies, these oral toxicities may nonetheless lead to significant morbidity and impact patients\u2019 quality of life, thereby compromising clinical outcomes. We conclude that familiarity with the spectrum of associated toxicities and understanding of their pathogenesis represent important areas of clinical research and may lead to better characterization, prevention, and management of these adverse events.<\/jats:p>","DOI":"10.3390\/ijms24098188","type":"journal-article","created":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T02:03:18Z","timestamp":1683165798000},"page":"8188","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Pathogenesis of Oral Toxicities Associated with Targeted Therapy and Immunotherapy"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1966-6000","authenticated-orcid":false,"given":"Alessandro","family":"Villa","sequence":"first","affiliation":[{"name":"Oral Medicine, Oral Oncology and Dentistry, Miami Cancer Institute, Baptist Health South Florida, Miami, FL 33176, USA"},{"name":"The Herbert Wertheim College of Medicine, Florida International University, Miami, FL 33176, USA"},{"name":"Department of Orofacial Sciences, University of California San Francisco, San Francisco, CA 94143, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3093-7801","authenticated-orcid":false,"given":"Michal","family":"Kuten-Shorrer","sequence":"additional","affiliation":[{"name":"Eastman Institute for Oral Health, University of Rochester Medical Center, Rochester, New York, NY 14642, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,5,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41392-021-00572-w","article-title":"Small molecules in targeted cancer therapy: Advances, challenges, and future perspectives","volume":"6","author":"Zhong","year":"2021","journal-title":"Signal. Transduct. Target. Ther."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ejphar.2018.07.034","article-title":"Molecular targeted therapy: Treating cancer with specificity","volume":"834","author":"Lee","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"lgz012","DOI":"10.1093\/jncimonographs\/lgz012","article-title":"Oral Mucosal Injury Caused by Targeted Cancer Therapies","volume":"2019","author":"Carrozzo","year":"2019","journal-title":"J. Natl. Cancer Inst. Monogr."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3322\/caac.21596","article-title":"A review of cancer immunotherapy toxicity","volume":"70","author":"Kennedy","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1080\/14656566.2020.1718652","article-title":"An update on pharmacotherapies in active development for the management of cancer regimen-associated oral mucositis","volume":"21","author":"Villa","year":"2020","journal-title":"Expert. Opin. Pharmacother."},{"key":"ref_6","first-page":"26","article-title":"Oral adverse events associated with targeted cancer therapies","volume":"66","author":"Chmieliauskaite","year":"2018","journal-title":"Gen. Dent."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3322\/caac.21704","article-title":"The broadening scope of oral mucositis and oral ulcerative mucosal toxicities of anticancer therapies","volume":"72","author":"Elad","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/CCO.0000000000000180","article-title":"Mucositis: Pathobiology and management","volume":"27","author":"Villa","year":"2015","journal-title":"Curr. Opin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.bbmt.2012.06.020","article-title":"Defining the role of sirolimus in the management of graft-versus-host disease: From prophylaxis to treatment","volume":"19","author":"Abouelnasr","year":"2013","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.cmet.2014.01.001","article-title":"Rapamycin: One drug, many effects","volume":"19","author":"Li","year":"2014","journal-title":"Cell Metab."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1592\/phco.24.13.1159.38094","article-title":"Current and future immunosuppressive strategies in renal transplantation","volume":"24","author":"Hardinger","year":"2004","journal-title":"Pharmacotherapy"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"112820","DOI":"10.1016\/j.ejmech.2020.112820","article-title":"Research progress of mTOR inhibitors","volume":"208","author":"Chen","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/cncr.24696","article-title":"Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients","volume":"116","author":"Sonis","year":"2010","journal-title":"Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/odi.12795","article-title":"Oral stomatitis and mTOR inhibitors: A review of current evidence in 20,915 patients","volume":"24","author":"Arena","year":"2018","journal-title":"Oral Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.bbmt.2014.11.680","article-title":"Mammalian target of rapamycin inhibitor-associated stomatitis in hematopoietic stem cell transplantation patients receiving sirolimus prophylaxis for graft-versus-host disease","volume":"21","author":"Villa","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.oraloncology.2011.08.009","article-title":"Clinical presentation and management of mTOR inhibitor-associated stomatitis","volume":"47","author":"Martins","year":"2011","journal-title":"Oral Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.oraloncology.2012.11.008","article-title":"A review of oral toxicity associated with mTOR inhibitor therapy in cancer patients","volume":"49","author":"Martins","year":"2013","journal-title":"Oral Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1002\/cam4.761","article-title":"Oral mucosal injury caused by mammalian target of rapamycin inhibitors: Emerging perspectives on pathobiology and impact on clinical practice","volume":"5","author":"Peterson","year":"2016","journal-title":"Cancer Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.4049\/jimmunol.181.6.3974","article-title":"Defects in skin gamma delta T cell function contribute to delayed wound repair in rapamycin-treated mice","volume":"181","author":"Mills","year":"2008","journal-title":"J. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/odi.12616","article-title":"On the pathogenesis of mTOR inhibitor-associated stomatitis (mIAS)-studies using an organotypic model of the oral mucosa","volume":"23","author":"Sonis","year":"2017","journal-title":"Oral Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"774103","DOI":"10.3389\/fimmu.2021.774103","article-title":"mTOR-Mediated Regulation of Immune Responses in Cancer and Tumor Microenvironment","volume":"12","author":"Mafi","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1007\/s00520-017-3629-4","article-title":"Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors","volume":"25","author":"Vigarios","year":"2017","journal-title":"Support. Care Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1200\/EDBK_289911","article-title":"Dermatologic Adverse Events of Systemic Anticancer Therapies: Cytotoxic Chemotherapy, Targeted Therapy, and Immunotherapy","volume":"40","author":"Deutsch","year":"2020","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1002\/cncr.24120","article-title":"Increased risk of high-grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy","volume":"115","author":"Tejwani","year":"2009","journal-title":"Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.critrevonc.2015.06.004","article-title":"Risk of grade 3-4 diarrhea and mucositis in colorectal cancer patients receiving anti-EGFR monoclonal antibodies regimens: A meta-analysis of 18 randomized controlled clinical trials","volume":"96","author":"Miroddi","year":"2015","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.oraloncology.2015.09.003","article-title":"Oral adverse events in cancer patients treated with VEGFR-directed multitargeted tyrosine kinase inhibitors","volume":"51","author":"Yuan","year":"2015","journal-title":"Oral Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"v139","DOI":"10.1093\/annonc\/mdv202","article-title":"Management of oral and gastrointestinal mucosal injury: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up","volume":"26","author":"Peterson","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.intimp.2018.06.001","article-title":"Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors","volume":"62","author":"Hargadon","year":"2018","journal-title":"Int. Immunopharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41573-021-00259-5","article-title":"Immune-related toxicities of checkpoint inhibitors: Mechanisms and mitigation strategies","volume":"21","author":"Sullivan","year":"2022","journal-title":"Nat. Rev. Drug. Discov."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1002\/cncr.33436","article-title":"Oral side effects of immune checkpoint inhibitor therapy (ICIT): An analysis of 4683 patients receiving ICIT for malignancies at Massachusetts General Hospital, Brigham & Women\u2019s Hospital, and the Dana-Farber Cancer Institute, 2011 to 2019","volume":"127","author":"Xu","year":"2021","journal-title":"Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40257-018-0384-3","article-title":"Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails","volume":"19","author":"Lacouture","year":"2018","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.6004\/jnccn.2020.7697","article-title":"Clinical Characteristics and Outcomes of Oral Mucositis Associated With Immune Checkpoint Inhibitors in Patients With Cancer","volume":"19","author":"Jacob","year":"2021","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune-checkpoint inhibitors: Long-term implications of toxicity","volume":"19","author":"Johnson","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/odi.13964","article-title":"Oral manifestations of immune-related adverse events in cancer patients treated with immune checkpoint inhibitors","volume":"28","author":"Klein","year":"2021","journal-title":"Oral Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/odi.13218","article-title":"Oral immune-related adverse events associated with PD-1 inhibitor therapy: A case series","volume":"26","author":"Shazib","year":"2020","journal-title":"Oral Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1200\/JOP.18.00005","article-title":"Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary","volume":"14","author":"Brahmer","year":"2018","journal-title":"J. Oncol. Pract."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e000213","DOI":"10.1136\/esmoopen-2017-000213","article-title":"Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer","volume":"2","author":"Granier","year":"2017","journal-title":"ESMO Open."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3389\/fphar.2017.00049","article-title":"Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy","volume":"8","author":"Kumar","year":"2017","journal-title":"Front. Pharmacol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ejca.2021.08.031","article-title":"Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy","volume":"157","author":"Dimitriou","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3389\/fonc.2018.00086","article-title":"Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations","volume":"8","author":"Seidel","year":"2018","journal-title":"Front. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Brahmer","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/09546630410015556","article-title":"Oral lichenoid eruption secondary to imatinib (Glivec)","volume":"15","author":"Ena","year":"2004","journal-title":"J. Dermatolog Treat."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00520-008-0536-8","article-title":"Skin and oral lesions associated to imatinib mesylate therapy","volume":"17","author":"Basso","year":"2009","journal-title":"Support. Care Cancer"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1634\/theoncologist.2014-0169","article-title":"Lichenoid mucosal reaction to rituximab","volume":"19","author":"Hochberg","year":"2014","journal-title":"Oncologist"},{"key":"ref_46","first-page":"3154856","article-title":"Oral Lichenoid Reaction: An Uncommon Side Effect of Rituximab","volume":"2019","author":"Giudice","year":"2019","journal-title":"Case Rep. Dent."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"4618","DOI":"10.1158\/1078-0432.CCR-21-2138","article-title":"Molecular Pathways and Mechanisms of BRAF in Cancer Therapy","volume":"28","author":"Poulikakos","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1001\/jamadermatol.2015.1745","article-title":"Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma","volume":"151","author":"Carlos","year":"2015","journal-title":"JAMA Dermatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1111\/bjd.13610","article-title":"Oral squamous cell carcinoma and hyperkeratotic lesions with BRAF inhibitors","volume":"172","author":"Vigarios","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1634\/theoncologist.2011-0198","article-title":"Characteristics of oral mucosal events related to bevacizumab treatment","volume":"17","author":"Gavrilovic","year":"2012","journal-title":"Oncologist"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"bcr2015211318","DOI":"10.1136\/bcr-2015-211318","article-title":"Geographical tongue induced by axitinib","volume":"2015","author":"Sundar","year":"2015","journal-title":"BMJ Case Rep."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1634\/theoncologist.2012-0320","article-title":"Geographic tongue induced by angiogenesis inhibitors","volume":"18","author":"Hubiche","year":"2013","journal-title":"Oncologist"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/jop.13064","article-title":"Is oral dysaesthesia a somatic symptom disorder?","volume":"49","author":"Kwong","year":"2020","journal-title":"J. Oral Pathol. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"5601","DOI":"10.1200\/JCO.2006.08.5415","article-title":"Targeted therapy for metastatic renal cell carcinoma","volume":"24","author":"Motzer","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1001\/jama.295.21.2516","article-title":"Sunitinib in patients with metastatic renal cell carcinoma","volume":"295","author":"Motzer","year":"2006","journal-title":"J. Am. Med. Assoc."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1111\/j.1365-2133.2009.09290.x","article-title":"Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib","volume":"161","author":"Lee","year":"2009","journal-title":"Br. J. Dermatol."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Porta, C., Paglino, C., Imarisio, I., Canipari, C., Chen, K., Neary, M., and Duh, M.S. (2011). Safety and treatment patterns of multikinase inhibitors in patients with metastatic renal cell carcinoma at a tertiary oncology center in Italy. BMC cancer, 11.","DOI":"10.1186\/1471-2407-11-105"},{"key":"ref_58","unstructured":"Atkinson, B.J., Perpich, J., Tannir, N.M., and Jonasch, E. (2010, January 5\u20137). Schedule modifications and treatment outcomes for sunitinib-related adverse events. Proceedings of the 2010 American Society of Medical Oncology 2010 Genitourinary Cancers Symposium, San Francisco, CA, USA."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"5035217","DOI":"10.1155\/2018\/5035217","article-title":"Stomatitis and VEGFR-Tyrosine Kinase Inhibitors (VR-TKIs): A Review of Current Literature in 4369 Patients","volume":"2018","author":"Arena","year":"2018","journal-title":"BioMed Res. Int."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1200\/JCO.2011.39.9394","article-title":"Efficacy and safety of regorafenib in patients with metastatic and\/or unresectable GI stromal tumor after failure of imatinib and sunitinib: A multicenter phase II trial","volume":"30","author":"George","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1634\/theoncologist.2010-0263","article-title":"Sunitinib in metastatic renal cell carcinoma: Recommendations for management of noncardiovascular toxicities","volume":"16","author":"Kollmannsberger","year":"2011","journal-title":"Oncologist"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1001\/archderm.144.1.123","article-title":"Sunitinib: A cause of bullous palmoplantar erythrodysesthesia, periungual erythema, and mucositis","volume":"144","author":"Suwattee","year":"2008","journal-title":"Arch. Dermatol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s10238-007-0145-8","article-title":"Uncovering Pandora\u2019s vase: The growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib","volume":"7","author":"Porta","year":"2007","journal-title":"Clin. Exp. Med."},{"key":"ref_64","first-page":"615","article-title":"Burning mouth syndrome","volume":"65","author":"Grushka","year":"2002","journal-title":"Am. Fam. Physician"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Mistretta, C.M., and Kumari, A. (2019). Hedgehog Signaling Regulates Taste Organs and Oral Sensation: Distinctive Roles in the Epithelium, Stroma, and Innervation. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20061341"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1111\/jdv.16230","article-title":"Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma: A joint expert opinion","volume":"34","author":"Dummer","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1152\/jn.00822.2014","article-title":"Hedgehog pathway blockade with the cancer drug LDE225 disrupts taste organs and taste sensation","volume":"113","author":"Kumari","year":"2015","journal-title":"J. Neurophysiol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ejca.2017.08.022","article-title":"Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial","volume":"86","author":"Hauschild","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1634\/theoncologist.2016-0186","article-title":"Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma","volume":"21","author":"Lacouture","year":"2016","journal-title":"Oncologist"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.lungcan.2015.01.018","article-title":"Successful treatment of crizotinib-induced dysgeusia by switching to alectinib in ALK-positive non-small cell lung cancer","volume":"88","author":"Koizumi","year":"2015","journal-title":"Lung Cancer"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(17)30565-2","article-title":"Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): An open-label, randomised phase 3 trial","volume":"390","author":"Hida","year":"2017","journal-title":"Lancet"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e002890","DOI":"10.1136\/jitc-2021-002890","article-title":"Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors","volume":"9","author":"Guidon","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e227722","DOI":"10.1001\/jamanetworkopen.2022.7722","article-title":"Association of Immune Checkpoint Inhibitors With Neurologic Adverse Events: A Systematic Review and Meta-analysis","volume":"5","author":"Farooq","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s13311-015-0401-7","article-title":"Immunotherapy in Peripheral Neuropathies","volume":"13","author":"Leger","year":"2016","journal-title":"Neurotherapeutics"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"774170","DOI":"10.3389\/fphar.2022.774170","article-title":"Neurologic Toxicity of Immune Checkpoint Inhibitors: A Review of Literature","volume":"13","author":"Albarran","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.2217\/fon.13.141","article-title":"Mammalian target of rapamycin inhibitor-associated stomatitis","volume":"9","author":"Treister","year":"2013","journal-title":"Future Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1111\/odi.14000","article-title":"Sicca syndrome associated with immune checkpoint inhibitor therapy","volume":"28","author":"Harris","year":"2022","journal-title":"Oral Dis."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1634\/theoncologist.2018-0823","article-title":"Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy","volume":"24","author":"Warner","year":"2019","journal-title":"Oncologist"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"e391","DOI":"10.1634\/theoncologist.2019-0467","article-title":"Sicca Syndrome Induced by Immune Checkpoint Inhibitor Therapy: Optimal Management Still Pending","volume":"25","author":"Sibaud","year":"2020","journal-title":"Oncologist"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrclinonc.2009.94","article-title":"Adverse effects of anticancer agents that target the VEGF pathway","volume":"6","author":"Chen","year":"2009","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1016\/S0049-3848(10)70014-1","article-title":"Bleeding complications of antiangiogenic therapy: Pathogenetic mechanisms and clinical impact","volume":"125","author":"Elice","year":"2010","journal-title":"Thromb. Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S1470-2045(09)70222-0","article-title":"Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: A systematic review and meta-analysis of clinical trials","volume":"10","author":"Je","year":"2009","journal-title":"Lancet Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1093\/annonc\/mdh068","article-title":"Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate","volume":"15","author":"Arora","year":"2004","journal-title":"Ann. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.oooo.2020.10.015","article-title":"The blue palate-A case series of imatinib-related oral pigmentation and literature review","volume":"131","author":"Donnell","year":"2021","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"685","DOI":"10.4103\/0253-7613.169576","article-title":"Imatinib-induced dental hyperpigmentation in chronic myeloid leukemia in an adult female","volume":"47","author":"Agrawal","year":"2015","journal-title":"Indian. J. Pharmacol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1468-3083.2008.02706.x","article-title":"Imatinib-associated hyperpigmentation, a side effect that should be recognized","volume":"23","author":"McPherson","year":"2009","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1007\/s00784-019-02886-0","article-title":"Association of oral mucosa hyperpigmentation with imatinib mesylate use: A cross-sectional study and a systematic literature review","volume":"23","author":"Oliveira","year":"2019","journal-title":"Clin. Oral Investig."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s12105-011-0325-4","article-title":"Mucosal pigmentation caused by imatinib: Report of three cases","volume":"6","author":"Li","year":"2012","journal-title":"Head Neck Pathol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/ors.12194","article-title":"Intraoral hyperpigmentation due to imatinib mesylate. A review of the.literature","volume":"9","author":"Pancholi","year":"2016","journal-title":"Oral Surgery"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S1470-2045(05)70243-6","article-title":"Cutaneous side-effects of kinase inhibitors and blocking antibodies","volume":"6","author":"Robert","year":"2005","journal-title":"Lancet Oncol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/9\/8188\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:28:45Z","timestamp":1760124525000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/9\/8188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,3]]},"references-count":90,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["ijms24098188"],"URL":"https:\/\/doi.org\/10.3390\/ijms24098188","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,3]]}}}